Therapeutic classes	Therapeutic subclasses	Therapeutic sub-subclasses	Restrictions
Hormones and substitutes	Corticosteroids		
Local anasthetics			
Skin and mucous membranes	Anti-infective agents	Antibacterial agents	
		Antifungals	
		Other local anti-infective agents	
	Anti-inflammatories		
	Antipruritics and local anesthetics		
	Protective agents – emollients – oils		
	Keratolytic agents		
	Keratoplastic agents		
	Skin and mucous membranes, various		
Other medications		Various others	

2. Any other medication, vitamin or natural health product intended for topical, injectable or oral administration that is not listed in Schedule I to the Regulation respecting the terms and conditions for the sale of medications (chapter P-10, r. 12).

3. Any combination and any extemporaneous mixture of medications, vitamins and natural health products of this Schedule, subject to applicable restrictions.

4. Any product for an extemporaneous mixture and any vehicle, solvent or adjuvant.

104103

Draft Regulation

Professional Code
(chapter C-26)

Medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients
— Amendment

Notice is hereby given, in accordance with sections 10 and 11 of the Regulations Act (chapter R-18.1), that the Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients, made by the Office des professions du Québec and appearing below, may be submitted to the Government for approval, with or without amendment, on the expiry of 45 days following this publication.

The draft Regulation updates the list of medications that podiatrists who obtained their permit to practise before 1976 may administer and prescribe. The Regulation also provides for transitional measures that apply to podiatrists who obtained their permit to practise on or after 1 January 1976.

The draft Regulation has no impact on the public or on enterprises, including small and medium-sized businesses.

Further information may be obtained by contacting Charles Gagnon, Direction de la veille et des orientations, Office des professions du Québec, 800, place D'Youville, 10e étage, Québec (Québec) G1R 5Z3; telephone: 418 643-6912 or 1 800 643-6912; email: charles.gagnon@opq.gouv.qc.ca.

Any person wishing to comment on the draft Regulation is requested to submit written comments within the 45-day period to the secretary of the Office des professions du Québec, Guylaine Couture, 800, place D'Youville, 10e étage, Québec (Québec) G1R 5Z3. The

comments will be forwarded by the Office to the Minister of Justice and may also be sent to interested persons, departments and bodies.

GUYLAINE COUTURE,
Secretary of the Office des professions du Québec

Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients

Podiatry Act
(chapter P-12, s. 12)

1. The Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients (chapter P-12, r. 6) is amended by replacing the title by the following:

"Regulation respecting the medications that a podiatrist who obtained a permit to practise before 1976 may administer or prescribe".

2. Section 1 is replaced by the following:

"**1.** A podiatrist who obtained a permit to practise before 1 January 1976 may, in the practice of the profession, administer or prescribe the medications listed in Schedule I.

2. Until (*insert the date occurring one year after the date of coming into force of this Regulation*), a podiatrist to who section 1 does not apply, who obtained a permit to practise before (*insert the date of coming into force of this Regulation*) and who has not yet undergone the training provided for in the Regulation respecting the medications that a podiatrist may administer or prescribe, approved by Order in Council (*insert the number and date of the Order in Council*) may, in the practice of the profession, administer or prescribe the medications listed in Schedules I and II.".

3. Schedule I is replaced by the following:

"**SCHEDULE I**
(*ss. 1 and 2*)

1. Any medication listed below, subject to the restrictions indicated:

Medications	Restrictions
Aluminium and its salts	
Amcinonide	
Anthralin	
Silver sulfadiazine	
Bacitracin and its salts	
Beclomethasone and its salts	
Benzalkonium	
Benzocaine	
Betamethasone dipropionate	
Betamethasone valerate	
Bupivacaine and its salts	Pharmaceutical form intended for administration by injection for local use only
Calcipotriol	
Calcitriol	
Camphor	
Cantharidin	
Cetirizine hydrochloride	
Chlorhexidine and its salts	
Ciclopirox olamine	
Cinchocaine (dibucaine)	
Clioquinol	
Clobetasol proprionate	
Clotrimazole	
Cyproheptadine hydrochloride	
Desonide	
Desoximetasone	
Diphenhydramine	Pharmaceutical form intended for oral and topical administration
Efinaconazole	

Medications	Restrictions
Epinephrine (adrenaline)	
Erythromycin	Powder extemporaneous mixture or topical preparation
Ethyl chloride	
Fluocinolone acetonide	
Fluocinode	
Formalin	
Framycetin sulfate	
Fusidic acid	
Gentamicin sulfate	
Mineral tar	
Vegetal tar	
Gramicidin	
Hexachlorophene	
Hydrocortisone and its salts	Pharmaceutical form intended for topical administration
Hydroxyzine hydrochloride	Pharmaceutical form intended for oral administration
Povidone iodine	
Ketoconazole	Pharmaceutical form intended for topical administration
Lactic acid	
Lidocaine and its salts	Pharmaceutical form intended for administration by injection for local use only
Loratadine	Pharmaceutical form intended for oral administration
Lorazepam	Pharmaceutical form intended for oral and sublingual administration
	Quantity limited to 4 tablets
Mepivacaine	Pharmaceutical form intended for administration by injection for local use only
Methylpolysiloxanes (dimethicone)	
Methylprednisolone acetate	
Miconazole nitrate	
Mometasone furorate	
Mupirocin	
Neomycin sulfate	
Nystatin, its salts and derivatives	Pharmaceutical form intended for topical administration
Dressings and products associated with the treatment of wounds and alterations of the skin and teguments	
Phenol	
Podophyllin	
Polymyxin B sulfate	
Pramoxine	
Promethazine hydrochloride	
Resorcinol and its salts	
Triethanolamine salicylate	
Salicylic acid	
Silicone (dimethicone)	
Sulphur colloidal	
Sulphur precipitate	
Sulphur sublimate	
Tazarotene	
Tolnaftate	
Triamcinolone acetonide	Pharmaceutical form intended for topical administration
Trichloroacetic acid	
Trimeprazine tartrate	
Urea	Pharmaceutical form intended for topical administration, with a concentration of 40% or less

2. Any other medication, vitamin and natural health product intended for topical or oral administration that is not listed in Schedule I of the Regulation respecting the terms and conditions for the sale of medications (chapter P-10, r. 12).

3. Any combination and any extemporaneous mixture of medications, vitamins and natural health products of this Schedule, subject to the applicable restrictions.".

4. Schedule II is amended

(1) by striking out "Amino acids" and "Calcium acetate";

(2) by replacing "Cantharin" by "Cantharidin";

(3) by striking out "Cetrimid", "Chlorphenesin", "Collagenase", "Desoxyribonuclease", "Econazole nitrate", "Fibrinolysin" and "Flumetasone pivalate";

(4) by replacing "0.1%" in the specification of substance "5-fluorouracil" by "5%";

(5) by striking out "Halcinodide" and its specification, "Iodine tincture", "Isopropyl myristate", "Mafenide and its salts", "Oxiconazole", "Rofecoxib" and its specifications, "Diethylamine salicylate", "Magnesium salicylate", "Synthetic sebum", "Sodium thiosulfate" and "Tioconazole".

5. This Regulation comes into force on the fifteenth day following the date of its publication in the *Gazette officielle du Québec*.

104102